Related Experiment Video
Updated: Jan 5, 2026
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Management of hepatitis B virus infection, updated Swedish guidelines
Johan Westin1, Soo Aleman2, Maria Castedal3
1Deparment of Infectious Diseases, Institute of Biomedicine at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Insights
Updated Swedish guidelines offer evidence-based strategies for managing hepatitis B virus (HBV) infection. These recommendations cover new treatments like tenofovir alafenamide (TAF) and special patient groups.
Area of Science:
- Hepatology
- Virology
- Public Health
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern, leading to chronic liver disease, hepatocellular cancer (HCC), and death.
- Despite available antiviral drugs and vaccines, effective management and timely treatment remain critical challenges.
Purpose of the Study:
- To provide updated, evidence-based guidelines for the treatment and management of HBV infection.
- To incorporate recent advancements, including the novel treatment option tenofovir alafenamide (TAF), and new principles in HBV management.
Main Methods:
- Review and synthesis of current evidence on HBV treatment and management.
- Development of updated recommendations by the Swedish Reference group for Antiviral Treatment (RAV).
Main Results:
- The guidelines address key aspects of HBV management, including diagnosis, treatment indications, and duration.
- Specific recommendations are provided for HCC surveillance, liver transplantation management, and HBV infection in pregnant women and children.
Conclusions:
- These updated guidelines offer a comprehensive framework for managing HBV infection, applicable both in Sweden and internationally.
- The guidelines aim to improve patient outcomes by ensuring optimal diagnosis, treatment, and monitoring of HBV infection.
Abstract:
Despite access to effective antiviral drugs and vaccines, hepatitis B virus (HBV) infection remains a major health issue worldwide. HBV is highly infectious and may cause chronic infection, progressive liver damage, hepatocellular cancer (HCC) and death. Early diagnosis, proper management and timing of treatment are crucial. The Swedish Reference group for Antiviral Treatment (RAV) here provides updated evidence-based guidelines for treatment and management of HBV infection which may be applicable also in other countries. Tenofovir alafenamide (TAF) has been introduced as a novel treatment option and new principles regarding indication and duration of treatment and characterization of hepatitis B have been gradually introduced which justifies an update of the previous guidelines from 2007. Updated guidelines on HCC surveillance in HBV-infected patients, treatment and prophylaxis for patients undergoing liver transplantation as well as management of pregnant women and children with HBV infection are also provided.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:26Standard Precaution
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...